{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:55:15Z","timestamp":1790060115919,"version":"4.0.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cytogfr.2023.06.003","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T18:25:56Z","timestamp":1687631156000},"page":"94-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Modulation of IL-33\/ST2 signaling as a potential new therapeutic target for cardiovascular diseases"],"prefix":"10.1016","volume":"71-72","author":[{"given":"Punniyakoti Veeraveedu","family":"Thanikachalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Ramamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poojitha","family":"Mallapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir Rama","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayaraj","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed AS","family":"Abourehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2023.06.003_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-9255-8-22","article-title":"Role of IL-33 in inflammation and disease","volume":"8","author":"Miller","year":"2011","journal-title":"J. Inflamm."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: the new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/cvr\/cvs015","article-title":"Reduction in IL-33 expression exaggerates ischaemia\/reperfusion-induced myocardial injury in mice with diabetes mellitus","volume":"94","author":"Rui","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2017.04.022","article-title":"Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress","volume":"138","author":"Veeraveedu","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/CIRCRESAHA.110.218867","article-title":"Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice","volume":"107","author":"Miller","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: Therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0014-5793(93)81333-U","article-title":"Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1","volume":"318","author":"Yanagisawa","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/j.1460-2075.1994.tb06367.x","article-title":"Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor","volume":"13","author":"Bergers","year":"1994","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.cytogfr.2023.06.003_bib10","first-page":"179","volume":"179","author":"Thomassen","year":"1995","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1432-1327.1999.00615.x","article-title":"Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells","volume":"264","author":"Iwahana","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1074\/jbc.271.1.124","article-title":"Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts","volume":"271","author":"G\u00e4chter","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1006\/bbrc.1999.1469","article-title":"Presence and expression of a novel variant form of ST2 gene product in human leukemic cell Line UT-7\/GM","volume":"264","author":"Tominaga","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbaexp.2004.08.013","article-title":"Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV","volume":"1681","author":"Iwahana","year":"2004","journal-title":"Biochim. Biophys. Acta Gene Struct. Expr."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib15","doi-asserted-by":"crossref","first-page":"27905","DOI":"10.1074\/jbc.270.46.27905","article-title":"ST2\/T1 protein functionally binds to two secreted proteins from Balb\/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1.","volume":"270","author":"Kumar","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0002-9440(10)63631-0","article-title":"Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules","volume":"163","author":"Baekkevold","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib18","article-title":"IL-33: a sheep in wolf\u2019s clothing?","volume":"2007","author":"Gadina","year":"2007","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib19","doi-asserted-by":"crossref","first-page":"19420","DOI":"10.1074\/jbc.M901744200","article-title":"Interleukin-33 is biologically active independently of caspase-1 cleavage","volume":"284","author":"Talabot-Ayer","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib20","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.4049\/jimmunol.180.8.5477","article-title":"The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines","volume":"180","author":"Sharma","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.immuni.2005.10.004","article-title":"An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor","volume":"23","author":"Dinarello","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib22","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1073\/pnas.95.12.6930","article-title":"T1\/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function","volume":"95","author":"L\u00f6hning","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.187.5.787","article-title":"Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells","volume":"187","author":"Xu","year":"1998","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2009.02.026","article-title":"IL-33-activated dendritic cells induce an atypical TH2-type response.","volume":"123","author":"Rank","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib25","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20071868","article-title":"IL-33 reduces the development of atherosclerosis.","volume":"205","author":"Miller","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib26","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.4049\/jimmunol.161.9.4866","article-title":"The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors","volume":"161","author":"Moritz","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib27","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation.","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/eurheartj\/ehm008","article-title":"Hypertrophy and inflammation: Too much for one heart","volume":"28","author":"Bayes-Genis","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib29","series-title":"Mechanisms of Disease: Pathologic Structural Remodeling Is More than Adaptive Hypertrophy in Hypertensive Heart Disease","author":"D\u00edez","year":"2005"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI108079","article-title":"Wall stress and patterns of hypertrophy in the human left ventricle","volume":"56","author":"Grossman","year":"1975","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib31","unstructured":"R. System, EUResearch Advances Series Pathological Hypertrophy and Cardiac Interstitium, (2015)."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib32","doi-asserted-by":"crossref","unstructured":"V.J. Dzau , R. Re , Editorial Tissue Angiotensin System in Cardiovascular Medicine A Paradigm Shift ? a tissue RAS would argue that these levels are too small, (1994).","DOI":"10.1161\/01.CIR.89.1.493"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib33","doi-asserted-by":"crossref","first-page":"46A","DOI":"10.1016\/0002-9149(93)90245-8","article-title":"Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation","volume":"71","author":"Klug","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib34","doi-asserted-by":"crossref","first-page":"36C","DOI":"10.1016\/0002-9149(94)90621-1","article-title":"Role of neurohormones in ventricular adaptation and failure","volume":"73","author":"Pouleur","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib35","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","article-title":"Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction","volume":"106","author":"Weinberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib36","doi-asserted-by":"crossref","DOI":"10.1084\/jem.188.8.1485","article-title":"Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells.","volume":"188","author":"Xu","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib37","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib38","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCHEARTFAILURE.109.873240","article-title":"Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling","volume":"2","author":"Seki","year":"2009","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib39","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1000520","article-title":"IL-33 reduces macrophage foam cell formation.","volume":"185","author":"McLaren","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.biocel.2013.11.008","article-title":"The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and pho","volume":"46","author":"Ashlin","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143064","article-title":"The Protective role of interleukin-33 in myocardial ischemia and reperfusion is associated with decreased HMGB1 expression and up-regulation of the P38 MAPK signaling pathway","volume":"10","author":"Ruisong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib42","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3892\/mmr.2014.2051","article-title":"IL-33 attenuates cardiac remodeling following myocardial infarction via inhibition of the p38 MAPK and NF-\u03baB pathways","volume":"9","author":"Yin","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.yjmcc.2016.12.010","article-title":"IL-33 enhances macrophage M2 polarization and protects mice from CVB3-induced viral myocarditis","volume":"103","author":"Wang","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/129486","article-title":"Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease","volume":"2012","author":"Abston","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib45","doi-asserted-by":"crossref","unstructured":"W.-Y. Chen, J. Hong, J. Gannon, R. Kakkar, R.T. Lee, Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33, Proc. Natl. Acad. Sci. 112 (2015) 7249\u20137254. doi:10.1073\/pnas.1424236112.","DOI":"10.1073\/pnas.1424236112"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pharmthera.2011.02.005","article-title":"The IL-33\/ST2 pathway \u2014 A new therapeutic target in cardiovascular disease","volume":"131","author":"Miller","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib47","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbadis.2015.04.011","article-title":"The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis","volume":"1852","author":"Buckley","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.atherosclerosis.2007.05.018","article-title":"ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques","volume":"196","author":"W\u00e5gs\u00e4ter","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib49","first-page":"8786","article-title":"Acute myocardial infarction and myocardial ischemia-reperfusion injury: a comparison","volume":"8","author":"Hashmi","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia-reperfusion injury: a neglected therapeutic target.","volume":"123","author":"Hausenloy","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0735-1097(02)01693-5","article-title":"Na+\/h+exchange inhibitors for cardioprotective therapy: progress, problems and prospects","volume":"39","author":"Avkiran","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0008-6363(98)00033-9","article-title":"A fresh look at reperfusion injury","volume":"38","author":"Piper","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib53","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1172\/JCI112160","article-title":"Myocardial reperfusion: a double-edged sword","volume":"76","author":"Braunwald","year":"1985","journal-title":"?, J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056089","article-title":"IL-33 attenuates anoxia\/reoxygenation-induced cardiomyocyte apoptosis by inhibition of PKC\u03b2\/JNK Pathway","volume":"8","author":"Rui","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib56","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/CIRCRESAHA.114.302653","article-title":"Cardiomyocyte-specific transforming growth factor \u03b2 suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction","volume":"114","author":"Rainer","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/pmj.77.903.4","article-title":"Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management.","volume":"77","author":"Kearney","year":"2001","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.78.22.12548-12556.2004","article-title":"Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis.","volume":"78","author":"Shen","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046515","article-title":"A20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-\u03baB signaling","volume":"7","author":"Gui","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib61","unstructured":"T.D.B. Dominic Titone, Nakon Aroonsakool, Jinghong Li, Justin P. Dumouchel, Sandra Lombardi, Nick H. Kim, David Poch, Fiona Murray, Increased Serum Interleukin-33 In Patients With Pulmonary Arterial Hypertension: A Role For IL-33\/ST2 In Disease Pathogenesis, in: B95. Nov. Ther. TARGETS Pulm. Hypertens. INSIGHTS FROM Transl. Preclin. Stud., American Thoracic Society, 2014: p. A3636. doi:10.1164\/AJRCCM-CONFERENCE.2014."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib62","doi-asserted-by":"crossref","unstructured":"C. Church, A. Mahmood, C. McSharry, D. Xu, A. Peacock, D.J. Welsh, An ST2\/IL-33 Transgenic Mouse Model Of Pulmonary Hypertension, in: C61. Pulm. Hypertens. Exp. Model. II, American Thoracic Society, 2011: pp. A4975\u2013A4975. doi:10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A4975.","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A4975"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/thx.2010.150953.5","article-title":"S154 Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension","volume":"65","author":"Shao","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbrc.2014.06.111","article-title":"Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension","volume":"451","author":"Shao","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib65","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jacc.2008.07.045","article-title":"Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research","volume":"52","author":"D\u00edez","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib66","first-page":"145","article-title":"Soluble ST2 testing: a promising biomarker in the management of heart failure","volume":"106","author":"Villacorta","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095055","article-title":"Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome","volume":"9","author":"Demyanets","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib68","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.ijcard.2012.05.073","article-title":"Pre-discharge risk stratification in unselected STEMI: Is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?","volume":"167","author":"Dhillon","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib69","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ahj.2011.03.025","article-title":"Interleukin 33 and ST2 in non\u2013ST-elevation myocardial infarction: comparison with global registry of acute coronary events risk scoring and NT-proBNP","volume":"161","author":"Dhillon","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib70","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1177\/15353702211034144","article-title":"Predictive values of sST2 and IL-33 for heart failure in patients with acute myocardial infarction","volume":"246","author":"Xing","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12265-017-9775-8","article-title":"The Interleukin-33\/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.","volume":"11","author":"Tseng","year":"2018","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib72","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.118.11157","article-title":"IL-33 (Interleukin 33)\/sST2 Axis in Hypertension and Heart Failure","volume":"72","author":"Ghali","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib73","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/clc.22262","article-title":"Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension.","volume":"37","author":"Zheng","year":"2014","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib74","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1253\/circj.CJ-13-1033","article-title":"Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension.","volume":"78","author":"Chida","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.repc.2016.08.005","article-title":"Prognostic stratification in pulmonary hypertension: A multi-biomarker approach","volume":"36","author":"Pl\u00e1cido","year":"2017","journal-title":"Rev. Port. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib76","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1373\/clinchem.2013.209858","article-title":"Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the ludwigshafen risk and cardiovascular health study","volume":"60","author":"Dieplinger","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1373\/clinchem.2011.173369","article-title":"Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial","volume":"58","author":"Kohli","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib78","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.jacc.2008.09.027","article-title":"Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load","volume":"52","author":"Bartunek","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib79","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1373\/clinchem.2014.227116","article-title":"Biomarkers of cardiovascular stress and subclinical atherosclerosis in the community","volume":"60","author":"Gopal","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib80","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.3760\/cma.j.issn.0366-6999.20130145","article-title":"Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction","volume":"126","author":"Zhang","year":"2013","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/eci.12282","article-title":"Modulation of IL-33\/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers","volume":"44","author":"S\u00e1nchez-M\u00e1s","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12265-013-9459-y","article-title":"ST2 as a cardiovascular risk biomarker: from the bench to the bedside","volume":"6","author":"Januzzi","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib83","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cca.2015.10.034","article-title":"Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction","volume":"452","author":"van der Velde","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cytogfr.2023.06.003_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.accreview.2004.07.124","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"13","author":"Shimpo","year":"2004","journal-title":"ACC Curr. J. Rev."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1479-5876-10-120","article-title":"Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress","volume":"10","author":"Zhang","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib86","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/MCA.0000000000000117","article-title":"Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease","volume":"25","author":"Liu","year":"2014","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3904\/kjim.2013.28.2.165","article-title":"Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction","volume":"28","author":"Guzel","year":"2013","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib88","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/498703","article-title":"IL-33\/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators","volume":"2013","author":"Caselli","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.cytogfr.2023.06.003_bib89","first-page":"29","article-title":"Serum levels of interleukin (IL)-33 in patients with ischemic heart disease.","volume":"6","author":"Jafarinia","year":"2018","journal-title":"MOJ Immunol."}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610123000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610123000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:02:33Z","timestamp":1761217353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610123000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":89,"alternative-id":["S1359610123000266"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2023.06.003","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of IL-33\/ST2 signaling as a potential new therapeutic target for cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2023.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}